$0.98
+0.04 (+3.77%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BCDA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 2 tracked-famous managers (SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC) · FINRA short interest 5.1 days to cover (settled 2026-07-31) · insider 90d: 5 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection FractionNCT06258447Primary Efficacy EndpointRandomized · Quadruple-masked · Treatment | Not applicable | Recruiting | Device: Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system | Ischemic Heart Failure | 250 | 2027-04-01 | in 225 d | 2026-02-09 |
| Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem CellsNCT05925608Treatment-emergent serious adverse eventsRandomized · Double-masked · Treatment | Phase 1/2 | Active, not recruiting | Combination product: CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) · Diagnostic test: Diagnostic Catheterization | Heart Failure, Systolic | 39 | Dec 2026 | ≤ 134 d | 2025-12-12 |
| CardiAMP Cell Therapy Chronic Myocardial Ischemia TrialNCT03455725Change from Baseline in Total Exercise Time on the treadmill using the Modified Bruce ProtocolRandomized · Quadruple-masked · Treatment | Not applicable | Active, not recruiting | Device: CardiAMP Cell Therapy System · Other: Sham Treatment | Refractory Angina, Chronic Myocardial Ischemia | 343 | 2025-02-19actual | — | 2026-01-06 |
| AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress TrialNCT05491681Number of product related adverse events through the duration of the study.Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: With available funding it was necessary for Sponsor to prioritize other studies. No study participants were consented or enrolled and no study sites were activated. | Biological: intravenous delivery of allogeneic bone marrow-derived MSCs | ARDS, Human | 0 | 2026-01-04actual | — | 2026-01-07 |
| CardiAMP™ Cell Therapy for Heart Failure TrialNCT02438306A composite endpoint based on a 3-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis.Randomized · Double-masked · Treatment | Phase 3 | Completed | Biological: Autologous cell therapy · Other: Sham | Heart Failure, Systolic | 125 | Feb 2025actual | — | 2025-09-19 |
| Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border ZoneNCT00507468Safety of treatmentNon-randomized · Open-label | Phase 1 | Completed | Procedure: Transendocaridal Transplantation of Autologous Bone Marrow | Ventricular Dysfunction, Myocardial Infarction | 20 | Mar 2009actual | — | 2009-11-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19